DrugPatentWatch Database Preview
Drugs in MeSH Category Nucleic Acid Synthesis Inhibitors
» See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-007 | Nov 27, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 062303-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-007 | Mar 24, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Mobius Therap | MITOSOL | mitomycin | FOR SOLUTION;TOPICAL | 022572-001 | Feb 7, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Forest Labs | FLUMADINE | rimantadine hydrochloride | SYRUP;ORAL | 019650-001 | Sep 17, 1993 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Antares Pharma Inc | OTREXUP PFS | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-010 | May 31, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-005 | Nov 7, 2014 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
